Ozempic Costs Slashed

Published: Monday, November 17, 2025 at 6:12 pm

Novo Nordisk Slashes Ozempic and Wegovy Prices in Limited-Time Offer

Novo Nordisk announced a temporary price reduction for Ozempic and Wegovy injections, effective November 17. The move aims to increase access to these medications, which are used to treat type 2 diabetes and, increasingly, for weight loss.

The introductory offer provides significant savings for new self-pay patients. For the lowest strength injections (0.25 mg and 0.5 mg), the out-of-pocket cost will be reduced to $199 per month for the first two months of treatment, before moving to a standard reduced price. This offer is available until March 31, 2026.

Existing self-pay patients will also benefit from the price cuts. The monthly cost for these patients will be reduced from $499 to $349, with the exception of the 2 mg Ozempic dose, which will remain at $499.

These savings will be accessible through over 70,000 pharmacies nationwide, as well as via home delivery and certain telehealth providers.

The company stated that the price reductions are intended to make FDA-approved versions of the drugs more affordable and to reduce the appeal of non-FDA-approved compounded semaglutide products. This announcement follows a recent agreement with the President, aimed at lowering prices for patients on Medicare and Medicaid.

Novo Nordisk's Executive Vice President, U.S. Operations, emphasized the company's commitment to ensuring affordability and accessibility of these medications. The company is also working to expand access through partnerships with telehealth providers and major retailers.

BNN's Perspective:

While the price reductions are a positive step towards improving access to these potentially life-changing medications, the limited-time nature of the offer raises concerns. A more sustainable, long-term solution is needed to ensure that these treatments are accessible to all who need them, regardless of their insurance status or financial situation. The focus on self-pay patients also highlights the ongoing challenges within the U.S. healthcare system.

Keywords: Ozempic, Wegovy, Novo Nordisk, price reduction, diabetes, weight loss, self-pay, medication, healthcare, affordability, FDA-approved, semaglutide, Medicare, Medicaid

Full Story